|
Enfuvirtide
resources
|
|
|
|
|
|
DRUG INFO
Enfuvirtide
Drug Name:
Enfuvirtide
Indication: For treatment of HIV AIDS
Pharmacology: Not Available
Mechanism Of Action: Not Available
Drug Category: Anti-HIV Agents
Brand Names/Synonyms: Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein;GP120; Transmembrane glycoprotein;GP41]; Fuzeon (Roche Pharmaceuticals)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
Chemical Formula: C202H298N50O64
Half Life: 3.8 +/- 0.6 hrs
Drug Type: Approved Drug
# Accession No: BIOD00106
CAS Registry Number: 159519-65-0
|
|
|
|
|
|
Enfuvirtide News
(When available)
Investigational boosted protease inhibitor, TMC114, works better ... Dec 20, 2005
EurekAlert (press release), Exciting interim data presented at the annual ICAAC* conference show that adding FUZEON (enfuvirtide) to the investigational boosted protease inhibitor (PI ...
Roche's Fuzeon/PI more than halves number of patients with ... Dec 20, 2005
Forbes BASEL (AFX) - Roche Holding AG said new interim data on HIV treatment Fuzeon (enfuvirtide) boosted by protease inhibitor (PI) TMC114/r shows more than a ...
New Data Show Two-Thirds of Patients Achieve Undetectable Viral ... Dec 19, 2005
PR Newswire (press release), ...an experimental boosted protease inhibitor (PI), TMC-114/ritonavir, were achieved in patients who initiated the drug in combination with FUZEON(R) (enfuvirtide ...
Investigational Boosted Protease Inhibitor, TMC114, Works Better ... Dec 20, 2005
APA OTS (Pressemitteilung), Basel, Switzerland (ots/PRNewswire) - - Power of "FUZEON effect" Provides Much Needed Hope for HIV Patients Facing Treatment Failure Exciting interim data ...
Biotechnology drug costs scrutinized Jan 3, 2006
Ventura County Star (subscription), ...for anemia, which costs about $36,000 a year, Serono SA and Pfizer Inc.'s Rebif for multiple sclerosis, at $25,000 a year, and Roche AG's Fuzeon for AIDS ...
(PRN) - Noble Appoints Andrew J. Tavi Deputy General Counsel ... ... Dec 19, 2005
Bolsamania.com, ...[+]. (PRN) - New Data Show Two-Thirds of Patients Achieve Undetectable Viral Load With FUZEON(R) and Investigational Protease Inhibitor ... [+. ...
Investigative Protease Inhibitor TMC114/R Overcomes Resistance in ... Dec 22, 2005
DG News Among patients who received enfuvertide (Fuzeon) for the first time along with TMC114 at the highest dose twice-daily, 64% achieved undetectable levels of HIV ...
(PRN) - Penwest Announces Results of Phase IIa Trial for PW2132 .. ... Dec 20, 2005
Bolsamania.com, Percent ... [+. PRN) - Investigational Boosted Protease Inhibitor, TMC114, Works Better in Combination With FUZEON(R) ... [. PRN ...
|
|
|
